Subtle differences in the molecular structure of mesogens can lead to very different experimental polymorphisms. The smectic C (SmC) phase can actually be exhibited by one isomer and not the other, or the range of temperature can be completely different. Unveiling the deep connection between atomic structure and the very existence of the SmC phase will lead to the design of new performing liquid crystalline materials for ferroelectric or nonlinear optical applications. Our approach is based on running molecular dynamics simulation from an initial SmC arrangement of molecules. When the temperature is increased, the molecules automatically adjust in a more favorable organization. Such modification in the imposed initial self-assembly is governed by values of the nonbonded energies. Thanks to the combined use of simulation and experimental phase diagrams, we have unveiled part of the deep connection between atomic structure and the very existence of the SmC phase. The actual display of the SmC mesophase stems from a subtle balance between short-range interactions, which reveal arrangement of molecules within a smectic layer, and long-range interactions, which disclose organization of layers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/jp5011605 | DOI Listing |
Unlabelled: Transparent and accurate reporting in early phase dose-finding (EPDF) clinical trials is crucial for informing subsequent larger trials. The SPIRIT statement, designed for trial protocol content, does not adequately cover the distinctive features of EPDF trials. Recent findings indicate that the protocol contents in past EPDF trials frequently lacked completeness and clarity.
View Article and Find Full Text PDFSoft Matter
January 2025
Dipartimento di Chimica e Chimica Industriale, University of Pisa, via Moruzzi 13, Pisa 56124, Italy.
In the field of chiral smectic liquid crystals, orthoconic antiferroelectric liquid crystals (OAFLCs) have attracted the interest of the scientific community due to the very high tilt angle, close to 45°, and the consequent optical properties. In the present study, the first H NMR investigation is reported on two samples, namely 3F5HPhF9 and 3F7HPhF8, showing the phase sequence isotropic-SmC*-SmC* and the phase sequence isotropic-SmA-SmC*-SmC*, respectively, when cooling from the isotropic to the crystalline phases. To this aim, the liquid crystals were doped with a small amount of deuterated probe biphenyl-4,4'-diol-d.
View Article and Find Full Text PDFTher Adv Hematol
January 2025
Sobi, Basel, Switzerland.
Background: More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B.
Objectives: We report final data from the B-SURE study, evaluating the real-world usage and effectiveness of rFIXFc in France.
Methods: Previously treated patients (all ages/severities) received on-demand or prophylactic rFIXFc during B-SURE.
Pharmaceuticals (Basel)
January 2025
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health, University of Genoa, 16132 Genova, Italy.
Background/objectives: This study aims to assess the effects of combined hormonal contraceptives (CHCs) on bone metabolism markers. It primarily measures osteocalcin and additionally examines other bone health markers, seeking to determine their responses to estrogen-progestogen treatments.
Methods: This study involved a comprehensive evaluation of the pertinent literature and a meta-analysis explicitly conducted on data describing women of reproductive age.
J Clin Neurol
January 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background And Purpose: This study was an open-label, dose-escalation, phase 1 clinical trial to determine the safety and dose of EN001 for patients with Duchenne muscular dystrophy (DMD). EN001, developed by ENCell, are allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells that originate at the umbilical cord, with preclinical studies demonstrating their high therapeutic efficacy for DMD.
Methods: This phase 1 clinical trial explored the safety and tolerability of EN001 as a potential treatment option for patients with DMD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!